SK Biopharmaceuticals Co., Ltd. (KRX:326030)

SK Biopharmaceuticals Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 15, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	8,669,277	8,700,602	7,862,650	5,646,385	7,612,048	13,234,939
Market Cap Growth	18.71%	10.66%	39.25%	-25.82%	-42.48%	-
Enterprise Value	8,540,496	8,637,734	7,807,605	5,442,304	7,267,516	12,840,764
Last Close Price	110700.00	111100.00	100400.00	72100.00	97200.00	169000.00
PE Ratio	33.87	36.14	-	-	117.39	-
Forward PE	44.08	73.81	-	-	-	-
PS Ratio	13.98	15.89	22.16	22.94	18.18	509.06
PB Ratio	14.12	15.16	24.50	17.84	17.14	34.92
P/TBV Ratio	14.77	16.24	29.59	18.86	17.90	36.83
P/FCF Ratio	85.84	93.05	-	-	-	-
P/OCF Ratio	83.98	91.68	-	-	-	-
EV/Sales Ratio	13.77	15.77	22.00	22.11	17.36	493.89
EV/EBITDA Ratio	67.22	75.93	-	-	68.18	-
EV/EBIT Ratio	78.11	89.66	-	-	76.53	-
EV/FCF Ratio	84.56	92.38	-	-	-	-
Debt / Equity Ratio	0.12	0.32	0.56	0.49	0.04	0.05
Debt / EBITDA Ratio	0.45	1.62	-	-	0.15	-
Debt / FCF Ratio	0.74	1.97	-	-	-	-
Asset Turnover	0.70	0.62	0.51	0.38	0.73	0.08
Inventory Turnover	0.36	0.40	0.35	0.53	0.60	0.13
Quick Ratio	1.54	1.26	1.47	2.28	2.64	5.67
Current Ratio	2.19	1.64	2.02	2.99	3.18	6.16
Return on Equity (ROE)	49.08%	50.72%	-11.10%	-36.66%	15.75%	-135.18%
Return on Assets (ROA)	10.38%	6.84%	-3.38%	-12.53%	10.38%	-46.83%
Return on Capital (ROIC)	14.56%	9.58%	-4.83%	-17.57%	13.84%	-60.65%
Return on Capital Employed (ROCE)	21.40%	15.00%	-	-	19.20%	-
Earnings Yield	2.95%	2.77%	-0.42%	-2.47%	0.85%	-1.87%
FCF Yield	1.17%	1.07%	-1.23%	-2.92%	-1.28%	-1.68%
Buyback Yield / Dilution	-	-	-	-	-9.12%	-10.41%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.